Delivery of antigens by viral vectors for vaccination

Therapeutic Delivery

Volumn 2, Issue 1, 2011, Pages 51-70

  Krause, Anja ^a   Worgall, Stefan ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA VACCINE; GLYCOPROTEIN; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; LENTIVIRUS VECTOR; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MUCIN 1; OUTER MEMBRANE PROTEIN F; PARVOVIRUS VECTOR; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT VACCINE;

ADAPTIVE IMMUNITY; ADENO ASSOCIATED VIRUS; ANTIBODY TITER; CHIMERA; CPG ISLAND; EBOLA HEMORRHAGIC FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INFLUENZA; INNATE IMMUNITY; LENTIVIRINAE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; SEROTYPE; TRANSGENE; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS ENTRY; VIRUS GENOME; VIRUS IMMUNITY; VIRUS LIKE AGENT;

EID: 79954531132     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.84     Document Type: Review

References (186)

1. Bruder JT, Stefaniak ME, Patterson NB, et al. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine 28(18), 3201-3210 (2010).
2. Chiuchiolo MJ, Boyer JL, Krause A, Senina S, Hackett NR, Crystal RG. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J. Infect. Dis. 194(9), 1249-1257 (2006). (Pubitemid 44630970)
3. Gallo P, Dharmapuri S, Cipriani B, Monaci P. Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther. 12(Suppl.), S84-S91 (2005). (Pubitemid 41541756)
4. Kim S, Jang JE, Yu JR, Chang J. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. Vaccine 28(22), 3801-3808 (2010).
5. Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346(2), 394-401 (2006). (Pubitemid 43357883)
6. Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev. Vaccines 6(2), 255-266 (2007). (Pubitemid 46613525)
7. Richardson JS, Yao MK, Tran KN, et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS. One 4(4), e5308 (2009).
8. Skaricic D, Traube C, De B, et al. Genetic delivery of an antiRSV antibody to protect against pulmonary infection with RSV. Virology 378(1), 79-85 (2008).
9. Boyer JL, Crystal RG. Genetic medicine strategies to protect against bioterrorism. Trans. Am. Clin. Climatol. Assoc. 117, 297-310 (2006).
10. Worgall S, Krause A, Qiu J, Joh J, Hackett NR, Crystal RG. Protective immunity to Pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J. Virol. 81(24), 13801-13808 (2007). (Pubitemid 350247873)
11. Zhang S, Liu Y, Fooks AR, Zhang F, Hu R. Oral vaccination of dogs (Canis familiaris) with baits containing the recombinant rabies-canine adenovirus type-2 vaccine confers long-lasting immunity against rabies. Vaccine 26(3), 345-350 (2008).
12. Vardas E, Kaleebu P, Bekker LG, et al. A Phase II study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res. Hum. Retroviruses 26(8), 933-942 (2010).
13. Barouch DH. Rational design of gene-based vaccines. J. Pathol. 208(2), 283-289 (2006). (Pubitemid 43126120)
14. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol. Ther. 17(8), 1333-1339 (2009).
15. Seregin SS, Amalfitano A. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin. Biol. Ther. 9(12), 1521-1531 (2009).
16. Appledorn DM, Patial S, McBride A, et al. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J. Immunol. 181(3), 2134-2144 (2008).
17. Yamaguchi T, Kawabata K, Koizumi N, et al. Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors. Hum. Gene Ther. 18(8), 753-762 (2007). (Pubitemid 47378072)
18. Zhu J, Huang X, Yang Y. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol. Ther. 16(7), 1300-1307 (2008). (Pubitemid 351866062)
19. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138(3), 576-591 (2009).
20. Nociari M, Ocheretina O, Schoggins JW, Falck-Pedersen E. Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J. Virol. 81(8), 4145-4157 (2007). (Pubitemid 46586909)
21. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J. Clin. Invest. 119(8), 2388-2398 (2009).
22. Muruve DA, Petrilli V, Zaiss AK, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452(7183), 103-107 (2008). (Pubitemid 351355095)
23. Appledorn DM, McBride A, Seregin S, et al. Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther. 15(24), 1606-1617 (2008).
24. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 109(7), 2832-2839 (2007). (Pubitemid 46482078)
25. Barouch DH, Pau MG, Custers JH, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-ad5 immunity. J. Immunol. 172(10), 6290-6297 (2004). (Pubitemid 38621236)
26. Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77(11), 6305-6313 (2003). (Pubitemid 36588400)
27. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther. 17(3), 295-304 (2010).
28. Yang TC, Millar JB, Grinshtein N, Bassett J, Finn J, Bramson JL. T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev. Vaccines 6(3), 347-356 (2007). (Pubitemid 46911598)
29. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77(1), 799-803 (2003). (Pubitemid 36005022)
30. Dharmapuri S, Peruzzi D, Aurisicchio L. Engineered adenovirus serotypes for overcoming antivector immunity. Expert Opin. Biol. Ther. 9(10), 1279-1287 (2009).
31. Sakurai H, Kawabata K, Sakurai F, Nakagawa S, Mizuguchi H. Innate immune response induced by gene delivery vectors. Int. J. Pharm. 354(1-2), 9-15 (2008). (Pubitemid 351400322)
32. Seiler MP, Cerullo V, Lee B. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr. Gene Ther. 7(5), 297-305 (2007). (Pubitemid 47595772)
33. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
34. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372(9653), 1894-1905 (2008).
35. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199(3), 381-390 (2009).
36. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 14(3), 316-327 (2006). (Pubitemid 44184972)
37. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther. 15(11), 808-816 (2008). (Pubitemid 351712613)
38. Romano G. Current development of adeno-associated viral vectors. Drug News Perspect. 18(5), 311-316 (2005). (Pubitemid 41491470)
39. Clark KR. Recent advances in recombinant adeno-associated virus vector production. Kidney Int. 61(1 Suppl.), S9-15 (2002). (Pubitemid 34155560)
40. Girard MP, Bansal GP. HIV/AIDS vaccines: a need for new concepts? Int. Rev. Immunol. 27(6), 447-471 (2008).
41. Johnson PR, Schnepp BC, Connell MJ, et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J. Virol. 79(2), 955-965 (2005). (Pubitemid 40053879)
42. Logan GJ, Wang L, Zheng M, Cunningham SC, Coppel RL, Alexander IE. AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection. Vaccine 25(6), 1014-1022 (2007). (Pubitemid 44937456)
43. Zhou L, Zhu T, Ye X, et al. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70. Hum. Gene Ther. 21(1), 109-119 (2010).
44. McCaffrey AP, Fawcett P, Nakai H, et al. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol. Ther. 16(5), 931-941 (2008). (Pubitemid 351587104)
45. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3(3), 306-312 (1997). (Pubitemid 27112928)
46. Yang Y, Haecker SE, Su Q, Wilson JM. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum. Mol. Genet. 5(11), 1703-1712 (1996). (Pubitemid 26372405)
47. Murphy SL, Li H, Mingozzi F, et al. Diverse IgG subclass responses to adeno-associated virus infection and vector administration. J. Med. Virol. 81(1), 65-74 (2009).
48. Lin J, Calcedo R, Vandenberghe LH, Bell P, Somanathan S, Wilson JM. A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque. J. Virol. 83(24), 12738-12750 (2009).
49. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr. Gene Ther. 7(5), 316-324 (2007). (Pubitemid 47595774)
50. Pien GC, Basner-Tschakarjan E, Hui DJ, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J. Clin. Invest. 119(6), 1688-1695 (2009).
51. Stieger K, Schroeder J, Provost N, et al. Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol. Ther. 17(3), 516-523 (2009).
52. Follenzi A, Santambrogio L, Annoni A. Immune responses to lentiviral vectors. Curr. Gene Ther. 7(5), 306-315 (2007). (Pubitemid 47595773)
53. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259), 263-267 (1996). (Pubitemid 26119138)
54. Pincha M, Sundarasetty BS, Stripecke R. Lentiviral vectors for immunization: an inflammatory field. Expert Rev. Vaccines 9(3), 309-321 (2010).
55. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC. Oral vaccination of mice with adenoviral vectors is not impaired by pre-existing immunity to the vaccine carrier. J. Virol. 77(20), 10780-10789 (2003). (Pubitemid 37204271)
56. Metharom P, Ellem KA, Wei MQ. Gene transfer to dendritic cells induced a protective immunity against melanoma. Cell Mol. Immunol. 2(4), 281-288 (2005).
57. Buffa V, Negri DR, Leone P, et al. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. Viral Immunol. 19(4), 690-701 (2006). (Pubitemid 46068062)
58. Buffa V, Negri DR, Leone P, et al. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice. J. Gen. Virol. 87(Pt 6), 1625-1634 (2006). (Pubitemid 43827216)
59. Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 97(1), 114-121 (2001). (Pubitemid 32061250)
60. Gruber A, Kan-Mitchell J, Kuhen KL, Mukai T, Wong-Staal F. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood 96(4), 1327-1333 (2000). (Pubitemid 30658460)
61. Jirmo AC, Koya RC, Sundarasetty BS, et al. Monocytes transduced with lentiviral vectors expressing hepatitis C virus nonstructural proteins and differentiated into dendritic cells stimulate multiantigenic CD8+ T cell responses. Vaccine 28(4), 922-933 (2010).
62. Zarei S, Leuba F, Arrighi JF, Hauser C, Piguet V. Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation. J. Allergy Clin. Immunol. 109(6), 988-994 (2002). (Pubitemid 34634310)
63. Zarei S, Abraham S, Arrighi JF, et al. Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivo. J. Virol. 78(14), 7843-7845 (2004). (Pubitemid 38915933)
64. Breckpot K, Emeagi PU, Thielemans K. Lentiviral vectors for anti-tumor immunotherapy. Curr. Gene Ther. 8(6), 438-448 (2008).
65. Dullaers M, Van MS, Heirman C, et al. Induction of effective therapeutic anti-tumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 13(7), 630-640 (2006).
66. Rowe HM, Lopes L, Ikeda Y, et al. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol. Ther. 13(2), 310-319 (2006). (Pubitemid 43056896)
67. Arce F, Rowe HM, Chain B, Lopes L, Collins MK. Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. Mol. Ther. 17(9), 1643-1650 (2009).
68. He Y, Falo LD. Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector. Immunol. Res. 36(1-3), 101-117 (2006). (Pubitemid 46398585)
69. Brown BD, Cantore A, Annoni A, et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 110(13), 4144-4152 (2007). (Pubitemid 351377775)
70. Markusic DM, van Til NP, Hiralall JK, Elferink RP, Seppen J. Reduction of liver macrophage transduction by pseudotyping lentiviral vectors with a fusion envelope from Autographa californica GP64 and Sendai virus F2 domain. BMC. Biotechnol. 9(85) (2009).
71. Pichlmair A, Reis e Sousa C. Innate recognition of viruses. Immunity. 27(3), 370-383 (2007). (Pubitemid 47418682)
72. Tillman BW, de Gruijl TD, Luykx-de Bakker SA, et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol. 162(11), 6378-6383 (1999). (Pubitemid 29309357)
73. Cheng C, Gall JG, Kong WP, et al. Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS. Pathog. 3(2), e25 (2007).
74. Okada N, Saito T, Masunaga Y, et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate anti-tumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res. 61(21), 7913-7919 (2001). (Pubitemid 33050987)
75. Wickham TJ, Tzeng E, Shears LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71(11), 8221-8229 (1997). (Pubitemid 27446397)
76. Worgall S, Busch A, Rivara M, et al. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J. Virol. 782572-2580 (2004).
77. Ding ZY, Wu Y, Luo Y, et al. Mannan-modified adenovirus as a vaccine to induce anti-tumor immunity. Gene Ther. 14(8), 657-663 (2007). (Pubitemid 46585625)
78. Thacker EE, Nakayama M, Smith BF, et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 27(50), 7116-7124 (2009).
79. Reyes-Sandoval A, Fitzgerald JC, Grant R, et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J. Virol. 78(14), 7392-7399 (2004). (Pubitemid 38915884)
80. Lemckert AA, Sumida SM, Holterman L, et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J. Virol. 79(15), 9694-9701 (2005). (Pubitemid 41022312)
81. Santra S, Sun Y, Korioth-Schmitz B, et al. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 27(42), 5837-5845 (2009).
82. Thorner AR, Lemckert AA, Goudsmit J, et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J. Virol. 80(24), 12009-12016 (2006). (Pubitemid 44904350)
83. Tatsis N, Lasaro MO, Lin SW, et al. Adenovirus vector-induced immune responses in non-human primates: responses to prime boost regimens. J. Immunol. 182(10), 6587-6599 (2009).
84. Boyer JL, Sofer-Podesta C, Ang J, et al. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. Hum. Gene Ther. 21(7), 891-901 (2010).
85. Ophorst OJ, Radosevic K, Klap JM, et al. Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine 25(35), 6501-6510 (2007). (Pubitemid 47198919)
86. Aurisicchio L, Ciliberto G. Patented cancer vaccines: the promising leads. Expert Opin. Ther. Pat. 20(5), 647-660 (2010).
87. Conforti A, Cipriani B, Peruzzi D, et al. A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. Vaccine 28(20), 3522-3530 (2010).
88. Dharmapuri S, Peruzzi D, Mennuni C, et al. Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in non-human primates. Mol. Ther. 17(10), 1804-1813 (2009).
89. Lubaroff DM, Karan D. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Adv. Drug Deliv. Rev. 61(3), 268-274 (2009).
90. Tosch C, Geist M, Ledoux C, et al. Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy. Cancer Gene Ther. 16(4), 310-319 (2009).
91. Sedlik C, Saron M, Sarraseca J, Casal I, Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl Acad. Sci. USA 94(14), 7503-7508 (1997). (Pubitemid 27345345)
92. Boisgerault F, Rueda P, Sun CM, Hervas-Stubbs S, Rojas M, Leclerc C. Cross-priming of T cell responses by synthetic microspheres carrying a CD8+ T cell epitope requires an adjuvant signal. J. Immunol. 174(6), 3432-3439 (2005). (Pubitemid 40354049)
93. Pattenden LK, Middelberg AP, Niebert M, Lipin DI. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol. 23(10), 523-529 (2005). (Pubitemid 41317916)
94. Dupuy C, Buzoni-Gatel D, Touze A, Bout D, Coursaget P. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J. Virol. 73(11), 9063-9071 (1999). (Pubitemid 29487059)
95. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347(21), 1645-1651 (2002). (Pubitemid 35340782)
96. Zhang LF, Zhou J, Chen S, et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18(11-12), 1051-1058 (2000).
97. Guo L, Zhou H, Wang M, et al. A recombinant adenovirus prime-virus-like particle boost regimen elicits effective and specific immunities against norovirus in mice. Vaccine 27(38), 5233-5238 (2009).
98. Villegas-Mendez A, Garin MI, Pineda-Molina E, et al. In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit anti-tumor immunity. Mol. Ther. 18(5), 1046-1053 (2010).
99. Huang X, Yang Y. Innate immune recognition of viruses and viral vectors. Hum. Gene Ther. 20(4), 293-301 (2009).
100. Logan GJ, Wang L, Zheng M, Ginn SL, Coppel RL, Alexander IE. Antigen-specific humoral tolerance or immune augmentation induced by intramuscular delivery of adeno-associated viruses encoding CTLA4-Ig-antigen fusion molecules. Gene Ther. 16(2), 200-210 (2009).
101. Du L, Zhao G, Lin Y, et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine 26(13), 1644-1651 (2008).
102. Cesco-Gaspere M, Zentilin L, Giacca M, Burrone OR. Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination. Scand. J. Immunol. 68(1), 58-66 (2008). (Pubitemid 351798403)
103. Hauck B, Chen L, Xiao W. Generation and characterization of chimeric recombinant AAV vectors. Mol. Ther. 7(3), 419-425 (2003). (Pubitemid 36503866)
104. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76(2), 791-801 (2002). (Pubitemid 34033377)
105. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin. Immunol. 92(1), 67-75 (1999). (Pubitemid 29315987)
106. Shiratsuchi T, Rai U, Krause A, Worgall S, Tsuji M. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents pre-existing immunity to adenovirus in mice. J. Clin. Invest. 120(10), 3688-701 (2010).
107. Ageichik A, Collins MK, Dewannieux M. Lentivector targeting to dendritic cells. Mol. Ther. 16(6), 1008-1009 (2008). (Pubitemid 351737063)
108. Koya RC, Kasahara N, Favaro PM, et al. Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J. Immunother. 26(5), 451-460 (2003). (Pubitemid 37128557)
109. Kobayashi M, Takaori-Kondo A, Fukunaga K, Miyoshi H, Uchiyama T. Lentiviral gp34/OX40L gene transfer into dendritic cells facilitates alloreactive CD4+ T-cell response in vitro. Int. J. Hematol. 79(4), 377-383 (2004). (Pubitemid 38738098)
110. Koya RC, Kimura T, Ribas A, et al. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol. Ther. 15(5), 971-980 (2007). (Pubitemid 46621656)
111. Koya RC, Weber JS, Kasahara N, et al. Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro. Hum. Gene Ther. 15(8), 733-748 (2004). (Pubitemid 39095246)
112. Kimura T, Koya RC, Anselmi L, et al. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol. Ther. 15(7), 1390-1399 (2007). (Pubitemid 46965335)
113. Yang L, Yang H, Rideout K, et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26(3), 326-334 (2008). (Pubitemid 351355129)
114. Gennari F, Lopes L, Verhoeyen E, Marasco W, Collins MK. Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells. Hum. Gene Ther. 20(6), 554-562 (2009).
115. D'Ambrosio E, Del Grosso N, Chicca A, Midulla M. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J. Hyg. Lond. 89(1), 155-161 (1982). (Pubitemid 12051350)
116. Hofmann C, Loser P, Cichon G, Arnold W, Both GW, Strauss M. Ovine adenovirus vectors overcome pre-existing humoral immunity against human adenoviruses in vivo. J. Virol. 3(8), 6930-6936 (1999). (Pubitemid 29327876)
117. Molnar-Kimber KL, Sterman DH, Chang M, et al. Impact of pre-existing and induced humoral and cellular immune responses in an adenovirus-based gene therapy Phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 9(14), 2121-2133 (1998). (Pubitemid 28463929)
118. Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 101(6), 1013-1019 (1998). (Pubitemid 28248886)
119. Vogels R, Zuijdgeest D, van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of pre-existing adenovirus immunity. J. Virol. 77(15), 8263-8271 (2003). (Pubitemid 36871454)
120. Abbink P, Lemckert AAC, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81(9), 4654-4663 (2007). (Pubitemid 46668663)
121. Harvey BG, Worgall S, Ely S, Leopold PL, Crystal RG. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3-adenovirus gene transfer vector. Hum. Gene Ther. 10(17), 2823-2837 (1999).
122. Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Characterization of human proliferative T cell responses to adenovirus. J. Infect. Dis. 171(5), 1090-1096 (1995).
123. Molinier-Frenkel V, Lengagne R, Gaden F, et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 76(1), 127-135 (2002). (Pubitemid 33138998)
124. Tan Y, Hackett NR, Boyer JL, Crystal RG. Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum. Gene Ther. 14, 1673-1682 (2003). (Pubitemid 37452877)
125. Tang J, Olive M, Cahmpagne K, et al. Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele. Gene Ther. 11, 1408-1415 (2004). (Pubitemid 39263894)
126. Mittal SK, Prevec L, Graham FL, Babiuk LA. Development of a bovine adenovirus type 3-based expression vector. J. Gen. Virol. 76(Pt 1), 93-102 (1995).
127. Bangari DS, Shukla S, Mittal SK. Comparative transduction efficiencies of human and non-human adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem. Biophys. Res. Commun. 327(3), 960-966 (2005). (Pubitemid 40092842)
128. Fitzgerald JC, Gao GP, Reyes-Sandoval A, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170(3), 1416-1422 (2003). (Pubitemid 36139509)
129. Moffatt S, Hays J, Hogen EH, Mittal SK. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 272(1), 159-167 (2000). (Pubitemid 30429439)
130. Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, Ertl HC. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J. Immunol. 171, 6774-6779 (2003). (Pubitemid 37532111)
131. Reddy PS, Idamakanti N, Hyun BH, Tikoo SK, Babiuk LA. Development of porcine adenovirus-3 as an expression vector. J. Gen. Virol. 80(Pt 3), 563-570 (1999). (Pubitemid 29101209)
132. Roy S, Gao G, Lu Y, et al. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum. Gene Ther. 15(5), 519-530 (2004). (Pubitemid 38639622)
133. Basnight M, Rogers NG, Gibbs CJ, Gajdusek DC. Characterization of four new adenovirus serotypes isolated from chimpanzee tissue explants. Am. J. Epidemiol. 94(2), 166-171 (1971).
134. Farina SF, Gao GP, Xiang ZQ, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol. 75(23), 11603-11613 (2001). (Pubitemid 33063252)
135. Kahl CA, Bonnell J, Hiriyanna S, et al. Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 28(35), 5691-702 (2010).
136. Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 25(11), 2074-2084 (2007). (Pubitemid 46227670)
137. Logunov DY, Zubkova OV, Karyagina-Zhulina AS, et al. Identification of HI-like loop in CELO adenovirus fiber for incorporation of receptor binding motifs. J. Virol. 81(18), 9641-9652 (2007). (Pubitemid 350067670)
138. Magalhaes I, Sizemore DR, Ahmed RK, et al. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS. One. 3(11), e3790 (2008).
139. Perreau M, Kremer EJ. The conundrum between immunological memory to adenovirus and their use as vectors in clinical gene therapy. Mol. Biotechnol. 34(2), 247-256 (2006). (Pubitemid 46030398)
140. Peruzzi D, Dharmapuri S, Cirillo A, et al. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 27(9), 1293-1300 (2009).
141. Pinto AR, Fitzgerald JC, Gao GP, Wilson JM, Ertl HC. Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector. Vaccine 22(5-6), 697-703 (2004). (Pubitemid 38114900)
142. Shott JP, McGrath SM, Pau MG, et al. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-g and antibody responses in mice. Vaccine 26(23), 2818-2823 (2008).
143. Xiang Z, Gao G, Reyes-Sandoval A, et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76(6), 2667-2675 (2002). (Pubitemid 34184852)
144. Xiang Z, Li Y, Cun A, et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12(10), 1596-1599 (2006) (Pubitemid 44570909)
145. Sharma A, Bangari DS, Tandon M, Pandey A, HogenEsch H, Mittal SK. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 386(1), 44-54 (2009).
146. Sharma A, Tandon M, Ahi YS, Bangari DS, Vemulapalli R, Mittal SK. Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther. 17(5), 634-642 (2010).
147. Singh N, Pandey A, Jayashankar L, Mittal SK. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol. Ther. 16(5), 965-971 (2008). (Pubitemid 351587108)
148. Gaydos CA, Gaydos JC. Adenovirus vaccines in the U.S. military. Mil. Med. 160(6), 300-304 (1995).
149. Lyons A, Longfield J, Kuschner R, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 26(23), 2890-2898 (2008).
150. Top FH Jr. Control of adenovirus acute respiratory disease in U.S. Army trainees. Yale J. Biol. Med. 48(3), 185-195 (1975).
151. Stone D, Liu Y, Li ZY, Tuve S, Strauss R, Lieber A. Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. Mol. Ther. 15(12), 2146-2153 (2007). (Pubitemid 350148931)
152. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 78(10), 5368-5381 (2004). (Pubitemid 38581487)
153. Liu J, Ewald BA, Lynch DM, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in Rhesus monkeys. J. Virol. 82(10), 4844-4852 (2008). (Pubitemid 351657046)
154. Liu J, O'Brien KL, Lynch DM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457(7225), 87-91 (2009).
155. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415(6869), 331-335 (2002). (Pubitemid 34087555)
156. Liu J, Ewald BA, Lynch DM, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82(10), 4844-4852 (2008). (Pubitemid 351657046)
157. Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol. Ther. 10(4), 616-629 (2004). (Pubitemid 39272851)
158. Tatsis N, Tesema L, Robinson ER, et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 13(5), 421-429 (2006).
159. Dudareva M, Andrews L, Gilbert SC, et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27(27), 3501-3504 (2009).
160. Cohen CJ, Xiang ZQ, Gao GP, Ertl HC, Wilson JM, Bergelson JM. Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J. Gen. Virol. 83(Pt 1), 151-155 (2002). (Pubitemid 34030819)
161. Varnavski AN, Schlienger K, Bergelson JM, Gao GP, Wilson JM. Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector. Hum. Gene Ther. 14(6), 533-544 (2003). (Pubitemid 36438938)
162. Nanda A, Lynch DM, Goudsmit J, et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and Rhesus monkeys. J. Virol. 79(22), 14161-14168 (2005). (Pubitemid 41552714)
163. Ophorst OJ, Kostense S, Goudsmit J, et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 22(23-24), 3035-3044 (2004). (Pubitemid 39037205)
164. Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174(11), 7179-7185 (2005). (Pubitemid 40705685)
165. Roberts DM, Nanda A, Havenga MJ, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing antivector immunity. Nature 441(7090), 239-243 (2006).
166. Krause A, Joh JH, Hackett NR, et al. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J. Virol. 80(11), 5523-5530 (2006).
167. McConnell MJ, Danthinne X, Imperiale MJ. Characterization of a permissive epitope insertion site in adenovirus hexon. J. Virol. 80(11), 5361-5370 (2006).
168. Worgall S, Krause A, Rivara M, et al. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J. Clin. Invest. 115(5), 1281-1289 (2005). (Pubitemid 40629047)
169. Matthews C, Jenkins G, Hilfinger J, Davidson B. Poly-l-lysine improves gene transfer with adenovirus formulated in PLGA microspheres. Gene Ther. 6(9), 1558-1564 (1999). (Pubitemid 29465514)
170. Campos SK, Parrott MB, Barry MA. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol. Ther. 9(6), 942-954 (2004). (Pubitemid 38878139)
171. Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J. Virol. 76(14), 6893-6899 (2002). (Pubitemid 41246204)
172. Le LP, Li J, Ternovoi VV, Siegal GP, Curiel DT. Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein. J. Gen. Virol. 86(Pt 12), 3201-3208 (2005). (Pubitemid 41685151)
173. Matthews QL, Yang P, Wu Q, et al. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol. J. 5(98) (2008).
174. Meulenbroek RA, Sargent KL, Lunde J, Jasmin BJ, Parks RJ. Use of adenovirus protein IX (pIX) to display large polypeptides on the virion-generation of fluorescent virus through the incorporation of pIX-GFP. Mol. Ther. 9(4), 617-624 (2004). (Pubitemid 38578812)
175. Vellinga J, de VJ, Myhre S, et al. Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid. Gene Ther. 14(8), 664-670 (2007). (Pubitemid 46585626)
176. Zaiss AK, Vilaysane A, Cotter MJ, et al. Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response. J. Immunol. 182(11), 7058-7068 (2009).
177. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 13(15), 1887-1900 (2002). (Pubitemid 35292683)
178. Lee SG, Yoon SJ, Kim CD, et al. Enhancement of adenoviral transduction with polycationic liposomes in vivo. Cancer Gene Ther. 7(10), 1329-1335 (2000).
179. Wortmann A, Vohringer S, Engler T, et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16(1), 154-162 (2007).
180. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8(5), 341-348 (2001). (Pubitemid 32241933)
181. Fisher KD, Seymour LW. HPMA copolymers for masking and retargeting of therapeutic viruses. Adv. Drug Deliv. Rev. 62(2), 240-245 (2010).
182. Huang D, Pereboev AV, Korokhov N, et al. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40+ cells. Gene Ther. 15(4), 298-308 (2007). (Pubitemid 351223466)
183. Pereboev AV, Nagle JM, Shakhmatov MA, et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol. Ther. 9(5), 712-720 (2004). (Pubitemid 38660424)
184. Perreau M, Guérin MC, Drouet C, Kremer EJ. Interactions between human plasma components and a xenogenic adenovirus vector: reduced immunogenicity during gene transfer. Mol. Ther. 15(11), 1998-2007 (2007). (Pubitemid 350011740)
185. Croyle MA, Patel A, Tran KN, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3(10), e3548 (2008).
186. Gene therapy trials worldwide. www.wiley.com/legacy/wileychi/genmed/ clinical